CN Patent

CN116019916A — 非小细胞肺癌靶点arid1a及其抑制剂在制备肺癌治疗药物中的用途

Assigned to First Affiliated Hospital of Bengbu Medical College · Expires 2023-04-28 · 3y expired

What this patent protects

本发明提供了非小细胞肺癌靶点ARID1A及其抑制剂在制备肺癌治疗药物中的用途。具体地，本发明提供了糖酵解抑制剂的用途，它被用于制备一组合物或制剂，所述的组合物或制剂用于：(a)预防和/或治疗肺癌，所述的肺癌是ARID1A阴性的肺癌；和/或(b)抑制肺癌细胞，所述的肺癌细胞是ARID1A阴性的肺癌细胞。本发明为肺癌治疗提供了新的有效治疗手段。

USPTO Abstract

本发明提供了非小细胞肺癌靶点ARID1A及其抑制剂在制备肺癌治疗药物中的用途。具体地，本发明提供了糖酵解抑制剂的用途，它被用于制备一组合物或制剂，所述的组合物或制剂用于：(a)预防和/或治疗肺癌，所述的肺癌是ARID1A阴性的肺癌；和/或(b)抑制肺癌细胞，所述的肺癌细胞是ARID1A阴性的肺癌细胞。本发明为肺癌治疗提供了新的有效治疗手段。

Drugs covered by this patent

Patent Metadata

Patent number
CN116019916A
Jurisdiction
CN
Classification
—
Expires
2023-04-28
Drug substance claim
No
Drug product claim
No
Assignee
First Affiliated Hospital of Bengbu Medical College
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.